GSK secures three lung cancer drug programs with FDA decisions on two frontrunners expected in 2026.
GSK will acquire clinical-stage biopharma company Nuvalent for $10.6 billion in an all-cash transaction. The deal values Nuvalent at $124 per share, a 40% premium over Monday’s closing price.
The acquisition marks GSK’s largest in over a decade and includes three non-small cell lung cancer programs. Two lead assets, zidesamtinib and neladalkib, face FDA decisions in September and November 2026, respectively. A third asset, NVL-330, remains in early-stage trials.
Nuvalent shares surged nearly 39% in premarket trading, while GSK’s stock fell over 3% in London. The company expects the deal to boost revenue and core operating profit starting in 2027.